In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Juno buys Stage Cell Therapeutics for €52mm plus €135mm in earn-outs

29 Sep 2020

Executive Summary

Juno Therapeutics Inc. paid €52mm ($59mm) in cash and issued 486k of its shares (valued at €20mm) to acquire the 95% of German biotech Stage Cell Therapeutics GMBH that it didn’t already down. Stage Cell will operate as a wholly owned subsidiary, and will be renamed Juno Therapeutics GMBH.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Partial Acquisition
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By